GenSci134 not checked
Changchun GeneScience Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.”In the company’s words, NCT07450001 on ClinicalTrials.gov
- Tested for
- Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Safety, Tolerability, Adult Growth Hormone Deficiency
- Main trialPhase 1/2
- “This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD. Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.”In the company’s words, NCT07450001 on ClinicalTrials.gov
Other drugs for Pediatric Growth Hormone Deficiency
- LUM-201Lumos Pharma · Phase 3
- GB06Kexing Biopharm Co., Ltd. · Phase 3
- InpegsomatropinXiamen Amoytop Biotech Co., Ltd. · Phase 2
- Recombinant Human Growth HormoneChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up3
- 25 NovPhase 1 trial completes · ClinicalTrials.gov
- 18 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 18 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 18 Jul 2028 | A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) | |
| Phase 1/2Not yet recruiting | 18 Jul 2028 | A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) | |
| Phase 1Recruiting | 25 Nov 2026 | A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026